The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01F | Monoclonal antibodies and antibody drug conjugates | |
4
|
L01FX | Other monoclonal antibodies | |
5
|
L01FX22 |
| Active Ingredient |
|---|
|
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19. Upon binding to CD19, loncastuximab tesirine is internalised followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. |
| Document | Type | Information Source | |
|---|---|---|---|
| ZYNLONTA Powder for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.